---
title: "Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means"
url: https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html
date: 2026-06-01
lang: en
category: "商業分析系列"
tags: ["Company Research","Radiopharma","Biotech business analysis","Drug development"]
summary: "Pluvicto's rapid growth shows radioligand therapy moving from specialist science into a real commercial infrastructure story, where isotope supply, hospital workflow, and patient selection become strategic assets."
json: https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.json
publisher: Drugnews｜藥時事 (https://drugnews.com.tw/)
---
This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers.

## Core Thesis

Pluvicto is not only a fast-selling oncology product. It is a signal that radioligand therapy is becoming an industrial system: isotope sourcing, manufacturing, logistics, imaging, physician workflow, and reimbursement must all work together before the market can scale.

## Why It Matters

For investors, radiopharma should be analyzed less like a normal oncology pill and more like a complex healthcare infrastructure business. The winners are likely to be companies that control supply chains, clinical evidence, hospital access, and commercial execution at the same time.

## Reading Framework

Drugnews reads this topic through five practical questions:

- What new evidence or business signal has actually changed?
- Which risks remain unresolved in clinical development, CMC, regulation, or commercialization?
- Does the event improve strategic optionality for partnership, licensing, financing, or M&A?
- Can the company convert scientific progress into durable market position?
- Does the information change valuation, or only create short-term attention?

## What To Watch Next

Readers should watch for follow-up data, trial design changes, safety signals, regulatory feedback, manufacturing readiness, payer response, competitive readouts, partnership activity, and whether management can turn the story into measurable execution.

## Original Chinese Edition

This English page is designed to make Drugnews analysis searchable and readable for English-language audiences while preserving the Chinese original as the primary source edition.

Read the original Chinese article: [核藥賣爆了](https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html)

This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.